About D2l Pharma Research Solutions Private Limited
Data last updated:
D2l Pharma Research Solutions Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 06 July 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2007PTC054728. Its GSTIN is 29AACCD6425B1ZY (Karnataka).
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹28.78 Lakh. It is led by directors including Kode Sashi Kiran (Managing Director) and Marella Ravikant (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H.No: 16 – 11 – 16/75 Plot No.75 Sripuram Colony Malakpet, Hyderabad, Telangana, India – 500036.
As per the financials filed for FY 2025, the company reported a revenue of ₹8.09 Cr, a growth of 19% compared to the previous year. For the same year it recorded a net loss of ₹68.6 Lakh (net margin -8.5%) and EBITDA of -₹38.27 Lakh (EBITDA margin -4.7%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 3% over five years.
The company has about 25 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: D2L Pharma Research Solutions. As per MCA filings, the company has open charges of ₹2.6 Cr and satisfied charges of ₹2.6 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website d2lpharma.com.
Company details
CIN history
D2l Pharma Research Solutions has one previous CIN (Corporate Identification Number): U24232AP2007PTC054728. The current CIN is U24232TG2007PTC054728, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2007PTC054728 | Current |
| U24232AP2007PTC054728 | Previous |
Contact details
D2l Pharma Research Solutions Private Limited's registered office is in Hyderabad, Telangana. Its website is d2lpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressH.No: 16 – 11 – 16/75 Plot No.75 Sripuram Colony Malakpet, Hyderabad, Telangana, India – 500036
- IndustryLife Sciences, Biotechnology
To see the full contact details of D2l Pharma Research Solutions Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
D2l Pharma Research Solutions operates one associated brand: D2L Pharma Research Solutions. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides consulting services for Key Opinion Leader development in pharmaceuticals. | d2lpharma.com |
Business activity
The main business activity of D2l Pharma Research Solutions is professional, scientific and technical. In detail, this covers management consultancy activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M3 | Management consultancy activities |
To see the full business activity and turnover split of D2l Pharma Research Solutions Private Limited, buy the company report.
Financials of D2l Pharma Research Solutions Private Limited
FY 2025 filings availableD2l Pharma Research Solutions Private Limited reported revenue of ₹8.09 Cr (up 19% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 19% growth in the latest year. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹38.27 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹68.6 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -4.7% | ||||
| Net Profit Margin | -8.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of D2l Pharma Research Solutions Private Limited, buy the company report.
Board of directors of D2l Pharma Research Solutions Private Limited
D2l Pharma Research Solutions has 4 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Marella Ravikant | Whole-Time Director | 05 Feb 2010 | 16 Years 9 Months | Current |
| Shekhar Gupta | Whole-Time Director | 18 Jan 2008 | 18 Years 9 Months | Current |
| Kode Sashi Kiran | Managing Director | 06 Jul 2007 | 19 Years 4 Months | Current |
| Sudheesh Kookkal | Additional Director | 27 Oct 2025 | 1 Years 0 Months | Current |
Auditor
D2l Pharma Research Solutions Private Limited is audited by MURALI & VENKAT for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MURALI & VENKAT | FY 2023 | 002162S |
Shareholding
The shareholding of D2l Pharma Research Solutions Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of D2l Pharma Research Solutions Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Apr 2020 | 100337127 | Others | ₹2.6 Cr | Satisfied |
To see the full charge records of D2l Pharma Research Solutions Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving D2l Pharma Research Solutions Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for D2l Pharma Research Solutions Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
D2l Pharma Research Solutions Private Limited has a workforce of 25 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 25 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of D2l Pharma Research Solutions Private Limited, buy the company report.
GST
D2l Pharma Research Solutions has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AACCD6425B1ZY | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of D2l Pharma Research Solutions Private Limited, buy the company report.
Recent activity
D2l Pharma Research Solutions Private Limited has 9 board changes on record since 2007: 4 appointments and 5 cessations. The latest: Sudheesh Kookkal was appointed as Additional Director on 27 Oct 2025.
3 earlier events are in the company report.
Frequently asked questions
D2l Pharma Research Solutions is an active private limited company based in Hyderabad, Telangana, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 06 July 2007 (19+ years old) and is registered under CIN U24232TG2007PTC054728.
D2l Pharma Research Solutions has 4 current directors:
- Kode Sashi Kiran - Managing Director
- Marella Ravikant - Whole-Time Director
- Shekhar Gupta - Whole-Time Director
- Sudheesh Kookkal - Additional Director
The latest financial statements of D2l Pharma Research Solutions on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of D2l Pharma Research Solutions is 29AACCD6425B1ZY, registered in Karnataka.
The CIN (Corporate Identification Number) of D2l Pharma Research Solutions is U24232TG2007PTC054728. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
D2l Pharma Research Solutions was incorporated on 06 July 2007, making it 19+ years old. It is registered with the Registrar of Companies, Hyderabad.
Sudheesh Kookkal was appointed as Additional Director on 27 Oct 2025. Ratna Kumari Kode ceased to be Director on 10 Oct 2012. Deepak Harikrishnan ceased to be Director on 02 Apr 2012. D2l Pharma Research Solutions has 9 board changes on record in total.
D2l Pharma Research Solutions can be reached through the website d2lpharma.com. Its registered office is in Hyderabad, Telangana, India.
The registered office of D2l Pharma Research Solutions is at H.No: 16 – 11 – 1675 Plot No.75 Sripuram Colony Malakpet, Hyderabad, Telangana, India – 500036.
D2l Pharma Research Solutions operates in the life sciences industry, in the biotechnology segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
